Clinical trials: Dementia of Alzheimer Type
Agitation in Patients With Dementia of the Alzheimer's Type
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04408755
- Testing
- AVP-786
- Where
- 95 sites in United States, Bulgaria and 9 more
- Volunteers
- 184 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia of Alzheimer Type
THE EFFECT OF REMOTE NURSING INTERVENTIONS BASED ON THE EMPOWERMENT PROCESS MODEL ON PEOPLE WITH DEMENTIA AND THEIR FAMILY CAREGIVERS
In this study, it is planned to evaluate the effect of remote nursing interventions based on the empowerment model on individuals with dementia and family caregivers. It was designed as a mixed method research.
- Trial name
- NCT07010874
- Testing
- REMOTE NURSING INTERVENTIONS BASED ON THE EMPOWERMENT PROCESS MODEL
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Gazi University
Osteoporosis
Autophagy and Pathological Aging
Autophagy is recognized as a central mechanism for the regulation of aging. . Osteoporosis (OA) and Alzheimer's disease (AD) are two forms of pathological aging, sometimes entangled, including an over-risk of OP in AD and…
- Trial name
- AVP (NCT03175874)
- Testing
- Hip bone sampling
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Alzheimer Disease
Far Infrared Treatment for Alzheimer's Disease
Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.
- Trial name
- NCT00599469
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.
Alzheimer Disease
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers.
- Trial name
- NCT03030105
- Testing
- BPN14770, Donepezil, Scopolamine 0.6 MG/ML
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Alzheimer Disease 1
Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture
To determine if adjunctive acupuncture acts as an AD treatment rather than a placebo.
- Trial name
- NCT05078944
- Testing
- Active acupuncture, Donepezil Hydrochloride
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Alzheimer Disease, Dementia of Alzheimer Type
Couples Lived Experience
This is a longitudinal study with regular quantitative assessments of all participants every six months for 3 years. The quantitative portion of the study will recruit couples, consisting of individuals over the age of 65 who are…
- Trial name
- NCT04863495
- Where
- 2 sites in United States
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Amyloid, Systemic Amyloidosis
Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)
This study is based on the hypothesis that MRI could make it possible to non-invasively detect these amyloid deposits at the level of the wrist using parametric sequences known as T1 mapping, in the form of an extension of T1 in…
- Trial name
- AMYLOCARP (NCT05150353)
- Testing
- MRI
- Where
- France
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Dementia, Dementia, Vascular
Factors Associated With Mortality, Morbidity and Prognosis in Dementia Patients
Dementia; It is a chronic syndrome characterized by a general and progressive deterioration in cognition, including memory, orientation, language, and comprehension.
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia of Alzheimer Type
- Trial name
- NCT05052450
- Testing
- Observational
- Volunteers
- 1,000 people
- Sponsor
- Gulhane Training and Research Hospital
Dementia, Mixed, Dementia, Vascular
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year period, compared with placebo, on markers of brain health.
- Conditions
- Dementia, Mixed, Dementia, Vascular, Dementia of Alzheimer Type, Cognitive Decline
- Trial name
- STAREE-Mind (NCT05586750)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- 2 sites in Australia
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Monash University
Memory Disorders, Age-Related, Retention Disorders, Cognitive
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.
- Trial name
- NCT00276510
- Testing
- EGb 761® (Tanakan®)
- Where
- 698 sites in France
- Volunteers
- 2,878 people
- Sponsor
- Ipsen
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203359
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Alzheimer Disease
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to donepezil in patients with mild to moderate dementia of Alzheimer's Type (DAT).
- Trial name
- DAT (NCT01822951)
- Testing
- Cerebrolysin, Donepezil
- Where
- Austria
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer Disease
Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type
Study to assess symptomatic efficacy, safety and tolerability of talsaclidine in patients with mild to moderate dementia of Alzheimer type
- Trial name
- NCT02249351
- Testing
- Talsaclidine
- Volunteers
- 54 people
- Sponsor
- Boehringer Ingelheim
Genetic Predisposition, Paraganglioma
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic…
- Conditions
- Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS
- Trial name
- NCT06377033
- Testing
- Behavioral nudge
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease, Dementia; Alzheimer's Type (Etiology)
Effects of Strength Exercise on Fall Risk in Elderly With Alzheimer's Disease
Interventional study to show the effects of strength exercise on fall risk in elderly with Alzheimer's disease
- Conditions
- Alzheimer Disease, Dementia; Alzheimer's Type (Etiology), Fall Risk, Elderly
- Trial name
- NCT04981587
- Testing
- Strength exercise, Usual treatment
- Where
- 2 sites in Spain
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Jaén
Alzheimer Disease, Dementia, Mixed
Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS
Agitation and aggression impose a tremendous burden on the individuals living with dementia, their families, caregivers, and healthcare systems.
- Conditions
- Alzheimer Disease, Dementia, Mixed, Dementia, Behavior Problem
- Trial name
- tTED (NCT03846492)
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Dementia, Alzheimer Disease
All About Me: An Intervention to Ease the Transition to Long Term Care
This Phase I study will involve initial development and evaluation of an innovative cross-platform software app called All About Me (AAM), which will consist of Serious Digital Health Games (SDHGs) for PWD.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Dementia, Mixed
- Trial name
- AAM (NCT05516134)
- Testing
- SAFE at Home
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Hopeful Aging
Cognitive Impairment, Cognitive Decline
Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)
This observational cohort study in healthy volunteers establishes normative data for the German version of the Montreal Cognitive Assessment (MoCA) and investigates the possible impacts of demographics on the MoCA total score.
- Conditions
- Cognitive Impairment, Cognitive Decline, Cognition Disorders, Cognitive Symptom
- Trial name
- MoCA-Norm (NCT03246269)
- Testing
- MoCA
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Andreas Monsch